1-(4-氯苯基)-3-(3-甲氧基苯基)脲 | 133611-97-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(4-氯苯基)-3-(3-甲氧基苯基)脲
• 英文名称: 1-(4-chlorophenyl)-3-(3-methoxyphenyl)urea
• 英文别名: 3‐(4‐chlorophenyl)‐1‐(3‐methoxyphenyl)urea
• CAS: 133611-97-9
• 化学式: C₁₄H₁₃ClN₂O₂
• 分子量: 276.722
• InChiKey: JSODWGRUZQBMNK-UHFFFAOYSA-N

物化性质

• 熔点：
  199-200 °C(Solv: ethanol (64-17-5))
• 沸点：
  327.3±27.0 °C(Predicted)
• 密度：
  1.344±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  1-(4-氯苯基)-3-(3-甲氧基苯基)脲 在 氢溴酸 、 溶剂黄146 作用下， 以88.6%的产率得到1-(4-chlorophenyl)-3-(3-hydroxyphenyl)urea
  参考文献：
  名称：

  Attenuation of Mycobacterium species through direct and macrophage mediated pathway by unsymmetrical diaryl urea

  摘要：

  Tuberculosis is a major threat for mankind and the emergence of resistance strain of Mycobacterium tuberculosis (Mtb) against first line antibiotics makes it lethal for human civilization. In this study, we have synthesized different diaryl urea derivatives targeting the inhibition of mycolic acid biosynthesis. Among the 39 synthesized molecules, compounds 46, 57, 58 and 86 showed MIC values <= 10 mu g/ml against H37Rv and mc(2)6030 strains. The best molecule with a methyl at ortho position of the first aromatic ring and prenyl group at the meta position of the second aromatic ring showed the MIC value of 5.2 mu g/ml and mu g/ml against H37Rv and mc(2)6030 respectively, with mammalian cytotoxicity of 163.4 mu g/ml. The effective compounds showed selective inhibitory effect on mycolic acid (epoxy mycolate) biosynthesis in C-14-radiolabelled assay. At the same time these molecules also executed their potent immunomodulatory activity by up-regulation of IFN-gamma and IL-12 and down-regulation of IL-10. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.09.083
• 作为产物：
  描述：

  对氯苯胺 、 3-甲氧基苯异氰酸 以 二氯甲烷 为溶剂， 以79.2%的产率得到1-(4-氯苯基)-3-(3-甲氧基苯基)脲
  参考文献：
  名称：

  Attenuation of Mycobacterium species through direct and macrophage mediated pathway by unsymmetrical diaryl urea

  摘要：

  Tuberculosis is a major threat for mankind and the emergence of resistance strain of Mycobacterium tuberculosis (Mtb) against first line antibiotics makes it lethal for human civilization. In this study, we have synthesized different diaryl urea derivatives targeting the inhibition of mycolic acid biosynthesis. Among the 39 synthesized molecules, compounds 46, 57, 58 and 86 showed MIC values <= 10 mu g/ml against H37Rv and mc(2)6030 strains. The best molecule with a methyl at ortho position of the first aromatic ring and prenyl group at the meta position of the second aromatic ring showed the MIC value of 5.2 mu g/ml and mu g/ml against H37Rv and mc(2)6030 respectively, with mammalian cytotoxicity of 163.4 mu g/ml. The effective compounds showed selective inhibitory effect on mycolic acid (epoxy mycolate) biosynthesis in C-14-radiolabelled assay. At the same time these molecules also executed their potent immunomodulatory activity by up-regulation of IFN-gamma and IL-12 and down-regulation of IL-10. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.09.083

文献信息

• [EN] DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS<br/>[FR] DIARYLURÉES EN TANT QUE MODULATEURS ALLOSTÉRIQUES DE CB1
  申请人：RTI INT

  公开号：WO2018209030A1

  公开（公告）日：2018-11-15

  The present invention provides novel diarylurea derivatives (compounds of formula (I)) and their uses. The compounds of the present invention are demonstrated to be allosteric modulators of the CB1 receptor, and therefore useful for the treatment of diseases and conditions mediated by CB1.

  本发明提供了新颖的二芳基脲衍生物（式（I）化合物）及其用途。本发明的化合物被证明是CB1受体的变构调节剂，因此对于治疗由CB1介导的疾病和症状是有用的。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DU CANCER
  申请人：UNIV DUKE

  公开号：WO2020123675A1

  公开（公告）日：2020-06-18

  This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.

  这份披露涉及化合物、包括它们的药物组合物，以及使用这些化合物和组合物治疗与热休克转录因子1（HSF1）活性和/或功能相关疾病的方法。更具体地，这份披露涉及使用这些化合物和药物组合物抑制HSF1活性的方法，以及治疗与HSF1活性和/或功能相关的疾病的方法，如癌症。
• Diaryl Ureas as CB1 Antagonists
  申请人：Hutchison Alan J.

  公开号：US20090239841A1

  公开（公告）日：2009-09-24

  Compounds of Formula I are provided. In which the variables are as described herein. Such compounds may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies and various in vitro assays.

  提供式I的化合物，其中变量如本文所述。这些化合物可用于体内或体外调节CB1活性，并且在治疗对CB1调节敏感的人类、家养伴侣动物和家畜动物的食欲障碍、肥胖和成瘾障碍方面特别有用。提供了用于治疗这些障碍的制药组合物和方法，以及用于受体定位研究和各种体外测定的配体的使用方法。
• N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION
  申请人：Aktas Bertal Huseyin

  公开号：US20120115915A1

  公开（公告）日：2012-05-10

  Compositions and methods for inhibiting translation initiation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using N,N′-diarylureas and/or N,N′-diarylthiourea compounds are described.

  本文提供了抑制翻译起始的组合物和方法。描述了使用N，N'-二芳基脲和/或N，N'-二芳基硫脲化合物治疗（1）细胞增生性疾病，（2）非增生性退行性疾病，（3）病毒感染和/或（4）与病毒感染相关的疾病的组合物、方法和试剂盒。
• Diarylureas as CB1 allosteric modulators
  申请人：Research Triangle Institute

  公开号：US11084781B2

  公开（公告）日：2021-08-10

  The present invention provides novel diarylurea derivatives (compounds of formula (I)) and their uses. The compounds of the present invention are demonstrated to be allosteric modulators of the CB1 receptor, and therefore useful for the treatment of diseases and conditions mediated by CB1.

  本发明提供了新型二芳脲衍生物（式（I）化合物）及其用途。本发明的化合物被证明是 CB1 受体的异位调节剂，因此可用于治疗由 CB1 介导的疾病和病症。